Hansa Biopharma — September 2023
-
From outsourced to in-house: Hansa Biopharma’s rising star on building an IR function
Irmagazine SEP 15, 2023
"Klaus Sindahl, head of IR at Hansa Biopharma, discusses how he took the firm’s IR strategy to the next level and won the trust of sell-side analysts"
-
Og følgende er nyt for mig, men også godt nyt for at kunne tiltrække kapital i US!:
New horizons
"In 2021, Hansa Biopharma announced it had confidentially filed for a potential US IPO and is now looking at 2024 as a potential year for the listing to come through. With roughly half its shareholder base made up of Swedish investors, Sindahl says a dual-listing would have more than one advantage."
"[We need investors]"
-
MB du er da velkommen til IKKE at læse og forholde dig til det og det ikke piveri det er fakta tror ikke jeg er den eneste der har det sådan men nok den eneste der udtrykker min mening om ledelsen/bestyrelsen godt vi lever i et land med ytringsfrihed nyd det MB god dag PS lad være med at læse min morgen hilsen når du opfatter det sådan
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind